← Leaderboards
Velimir A Luketic
Virginia Commonwealth University
$438,753
Attributed
$438,753
Total exposure
21
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $83.5K · FY2005–10$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$438,753 · 21
By mechanism
M01$438,753 · 21
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Arun J Sanyal$37,042,537
- Phillip B Hylemon$8,797,545
- Alphonse E Sirica$7,545,503
- Douglas Heuman$148,636
- Paul Dent$11,860,656
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseResourcesGrantUnited States National Institutes Of HealthSourceInstitutionLiverLiver TransplantationUrsodeoxycholic AcidClinical ResearchImmuneInjuryClinical TrialsPrimary Sclerosing CholangitisCessation Of LifePurposeBloodAdultTissuesLiver DiseasesResearch StudyConsent Forms
Grant awards (24)
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$23,677
M01 · FY2010 · RR · contact PI
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$3,866
M01 · FY2010 · RR · contact PI
STUDIES OF PRIMARY SCLEROSING CHOLANGITIS (STOPSC)$806
M01 · FY2010 · RR · contact PI
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$63,449
M01 · FY2009 · RR · contact PI
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$17,729
M01 · FY2009 · RR · contact PI
STUDIES OF PRIMARY SCLEROSING CHOLANGITIS (STOPSC)$2,333
M01 · FY2009 · RR · contact PI
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$55,748
M01 · FY2008 · RR · contact PI
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$14,032
M01 · FY2008 · RR · contact PI
DATABASE ON PTS WHO RECEIVE ORTHOTOPIC LIVER TRANSPLANTATION FOR HEP B$5,689
M01 · FY2008 · RR · contact PI
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$43,894
M01 · FY2007 · RR · contact PI
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$17,909
M01 · FY2007 · RR · contact PI
DATABASE ON PTS WHO RECEIVE ORTHOTOPIC LIVER TRANSPLANTATION FOR HEP B$4,214
M01 · FY2007 · RR · contact PI
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$43,633
M01 · FY2006 · RR · contact PI
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$18,022
M01 · FY2006 · RR · contact PI
DATABASE ON PTS WHO RECEIVE ORTHOTOPIC LIVER TRANSPLANTATION FOR HEP B$3,478
M01 · FY2006 · RR · contact PI
NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS AFTER TREATMENT WITH METHOTREXATE$33,422
M01 · FY2005 · RR
HIGH DOSE UDCA FOR PRIMARY SCLEROSING CHOLANGITIS$21,167
M01 · FY2005 · RR
URSODEOXYCHOLIC ACID &METHORTREXATE IN BILIARY CIRRHOSIS$11,884
M01 · FY2005 · RR
DATABASE ON PTS WHO RECEIVE ORTHOTOPIC LIVER TRANSPLANTATION FOR HEP B$4,085
M01 · FY2005 · RR
Ursodeoxycholic Acid &Methortrexate in Biliary Cirrhosis$36,487
M01 · FY2004 · RR
High Dose UDCA for Primary Sclerosing Cholangitis$10,065
M01 · FY2004 · RR
Database on pts who receive orthotopic liver transplant$2,516
M01 · FY2004 · RR
HBIG AS IMMUNOPROPHYLAXIS FOR RECURRENT HEPATITIS B FOLLOWING ORTHOTO$0
M01 · FY2001 · RR
HBIG AS IMMUNOPROPHYLAXIS FOR RECURRENT HEPATITIS B FOLLOWING ORTHOTO$648
M01 · FY2000 · RR